Surmodics, Inc. (NASDAQ:SRDX) Q2 2024 Earnings Call Transcript
Surmodics, Inc. beats earnings expectations. Reported EPS is $0.01742, expectations were $-0.36. Surmodics, Inc.
Surmodics Inc (SRDX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Soleus Capital Guy Levy | 789,060 | $24,090,002 | +101% | 1.73% |
| 2. | Hudson Bay Capital Management Sander Gerber | 464,969 | $14,195,504 | +55% | 0.04% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 269,392 | $8,224,538 | +117% | 0.01% |
| 4. | Millennium Management Israel Englander | 206,487 | $6,304,048 | +72% | 0% |
| 5. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 144,043 | $4,397,632 | +117% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.36 | 1,500 | $30,535.50 | 4,800 | 2014-05-08 | Filing | |
| $11.01 | 500 | $5,505.00 | 500 | 2010-12-15 | Filing | |
| $19.09 | 2,625 | $50,111.25 | 2,625 | 2009-02-10 | Filing | |
| $18.98 | 52 | $986.96 | 500 | 2009-02-09 | Filing | |
| $18.97 | 448 | $8,498.56 | 448 | 2009-02-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.44 | 7,009 | $276,453.18 | 70,350 | 2024-11-26 | Filing | |
| $34.89 | 4,366 | $152,321.01 | 24,192 | 2022-11-28 | Filing | |
| $33.48 | 2,733 | $91,511.23 | 30,179 | 2022-11-11 | Filing | |
| $33.00 | 2,773 | $91,506.50 | 34,178 | 2022-11-14 | Filing | |
| $45.55 | 100 | $4,555.00 | 155,041 | 2022-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,157,225 | $35,330,080 | 0% | |
| 2. | 849,354 | $25,930,778 | 0.01% | |
| 3. | 798,675 | $24,383,548 | 0% | |
| 4. | 675,989 | $20,637,954 | 0% | |
| 5. | 395,509 | $12,074,890 | 0.09% |
News See All
Surmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call Transcript
Operator: Welcome everyone to the Surmodics First Quarter of Fiscal Year 2024 Earnings Call. Please note that this call is being webcast.
Surmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Call Transcript
Operator: Welcome everyone to Surmodics Fourth Quarter and Fiscal Year 2023 Earnings Call. Please note that this call is being webcast.
Surmodics, Inc. (NASDAQ:SRDX) Q3 2023 Earnings Call Transcript
Operator: Welcome everyone to Surmodics Third Quarter of Fiscal Year 2023 Earnings Call. Please note that this call is being webcast.
Surmodics, Inc. (NASDAQ:SRDX) Q2 2023 Earnings Call Transcript
Operator: Welcome everyone to Surmodics’ Second Quarter and Fiscal Year 2023 Earnings Call. Please note that this call is being webcast.
Surmodics, Inc. (NASDAQ:SRDX) Q1 2023 Earnings Call Transcript
Operator: Welcome everyone to Surmodics' First Quarter of Fiscal Year 2023 Earnings Call. Please note that this call is being webcast.
Is SRDX A Good Stock To Buy Now?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Do Hedge Funds Love SurModics, Inc. (SRDX)?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Should You Avoid SurModics, Inc. (SRDX)?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November.
Here's What Hedge Funds Think About SurModics, Inc. (SRDX)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June.